Anders Romare, Advisory Board Member, causaLens, and former Novo Nordisk CDIO, outlines why artificial intelligence represents a structural turning point for the pharmaceutical industry.
Anders Romare
Advertisement
Articles by Anders Romare
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
2
GSK Enters $2.2 Billion Definitive Agreement to Acquire RAPT Therapeutics
3
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer
4
Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics
5